X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-24-2024-1488.pdf
https://www.globenewswire.com//news-release/2024/03/12/2844471/0/en/NewAmsterdam-Pharma-Doses-First-Patient-in-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-and-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-13-2023-60327.pdf
https://www.prnewswire.com/news-releases/miller-law-llc-and-motley-rice-llc-announce-a-proposed-settlement-in-in-re-zetia-ezetimibe-antitrust-litigation-301863674.html
https://www.globenewswire.com/news-release/2023/06/03/2681526/0/en/NewAmsterdam-Pharma-Presents-Full-Data-from-Phase-2-ROSE2-Trial-Evaluating-Obicetrapib-in-Combination-with-Ezetimibe-as-an-Adjunct-to-High-Intensity-Statin-Therapy-at-NLA-Scientifi.html
https://www.fiercepharma.com/pharma/merck-and-glenmark-wrap-zetia-pay-delay-case-after-pharmacies-take-settlement#:~:text=via%20Getty%20Images)-,Merck%20%26%20Co.,clutch%20of%20retail%20pharmacy%20holdouts.
https://www.fiercepharma.com/pharma/merck-glenmark-headed-court-after-judge-scraps-bid-summary-judgment-zetia-antitrust-lawsuit
https://endpts.com/newamsterdam-notches-another-win-in-resurrection-of-amgen-cardio-drug/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215693
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210859
https://www.lexblog.com/2022/06/23/fda-issues-untitled-letter-to-althera-pharmaceuticals-statements-relating-to-roszet/
https://endpts.com/fda-slams-small-pharma-for-misleading-ad-with-a-dearth-of-safety-info-and-dubious-stat-calculations/
https://www.esperion.com/news-releases/news-release-details/esperion-supports-collaborative-study-integrated-and-learning
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-17-2021-1637135168.pdf
https://www.einnews.com/pr_news/555914224/now-available-generic-ezetimibe-rosuvastatin-combination-tablets-in-a-trial-80-of-chd-patients-reached-ldl-c-goal
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-11-2021-1636538960.pdf
https://finance.yahoo.com/finance/news/esperion-chops-40-workforce-launch-215424232.html
https://www.prweb.com/releases/fda_approves_altheras_roszet_rosuvastatin_and_ezetimibe_tablets_a_new_oral_therapy_for_powerful_cholesterol_reduction/prweb17832549.htm
http://www.pharmatimes.com/news/uk_approval_for_daiichi_sankyos_cholesterol-lowering_treatments_1365458#:~:text=UK%20approval%20for%20Daiichi%20Sankyo's%20cholesterol%2Dlowering%20treatments,-18th%20March%202021&text=Daiichi%20Sankyo's%20cholesterol%2Dlowering%20drugs,for%20use%20on%20the%20NHS.
https://www.streetinsider.com/Corporate+News/Esperion+Therapeutics+%28ESPR%29+Announces+EC+Approval+of+NUSTENDI+Tablet+for+Treatment+of+Hypercholesterolemia+and+Mixed+Dyslipidemia/16712005.html
https://www.globenewswire.com/news-release/2020/03/23/2004649/0/en/Esperion-Announces-Pooled-Analyses-from-Phase-3-LDL-C-Lowering-Development-Program-of-the-NEXLETOL-bempedoic-acid-Tablet-and-Phase-2-Study-Results-of-the-NEXLIZET-bempedoic-acid-an.html
http://www.pmlive.com/pharma_news/esperion_gets_fda_thumbs_up_for_cholesterol_drug_nexletol_1326819
http://www.pharmatimes.com/news/givlaari,_nubeqa_among_jan_chmp_decisions_1323999
https://endpts.com/medco-builds-its-case-for-star-cholesterol-rnai-therapy-with-two-new-positive-pivotal-studies/
https://www.contractpharma.com/contents/view_breaking-news/2019-08-29/esperions-bempedoic-acid-ezetimibe-tablet-achieves-positive-phase-ii-results/
https://endpts.com/armed-with-stellar-if-niche-phiii-data-regeneron-steers-breakthrough-cholesterol-drug-to-post-pcsk9-waters/
https://www.biospace.com/article/esperion-and-oberland-capital-announce-200-million-funding-agreement/?s=75
https://www.prnewswire.com/news-releases/daiichi-sankyo-europe-and-esperion-announce-validation-of-the-marketing-authorisation-application-maa-for-bempedoic-acid-and-the-bempedoic-acid--ezetimibe-fixed-dose-combination-tablet-300804050.html
https://www.biopharmadive.com/news/esperion-bempedoic-acid-daiichi-license-cholesterol/545236/
https://www.ema.europa.eu/documents/scientific-guideline/draft-ezetimibe-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf
https://www.ema.europa.eu/en/clinical-development-fixed-combination-medicinal-products
https://health.economictimes.indiatimes.com/news/policy/new-drug-options-risk-factors-added-to-u-s-heart-guidelines/66573670
https://health.economictimes.indiatimes.com/news/policy/new-drug-options-risk-factors-added-to-u-s-heart-guidelines/66573670
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211550
https://www.biopharmadive.com/news/merck-ceo-to-stay-on-through-2019/533275/
https://www.law360.com/lifesciences/articles/1067928/lawyers-compete-to-represent-zetia-buyers-in-antitrust-case?nl_pk=d3899bd1-6cde-48ff-8abe-0c7406f73b0b&utm_source=newsletter&utm_medium=email&utm_campaign=lifesciences
https://www.thepharmaletter.com/in-brief/brief-ftc-imposes-conditions-on-amneal-acquisition-of-impax
https://www.fiercebiotech.com/biotech/esperion-s-ldl-med-aces-a-third-pivotal-trial
https://www.biopharmadive.com/news/to-shame-drugmakers-cms-publicizes-price-hikes/523693/
https://www.prnewswire.com/news-releases/ani-pharmaceuticals-completes-acquisition-of-generic-products-and-assets-from-amnealimpax-300642867.html
https://www.forbes.com/sites/johnlamattina/2018/03/12/in-cholesterol-drug-battle-sanofiregeneron-jolt-prospects-of-the-medicines-company-and-esperion/#213bdaf07772
https://www.biospace.com/article/esperion-s-cholesterol-drug-positive-in-phiii-trial/
Market Place
Share 
